Oxaspiro[2.5]octane derivatives and analogs
US-9328082-B2 · May 3, 2016 · US
Oxaspiro[2.5]octane derivatives and analogs
US10259796B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10259796-B2 |
| Application number | US-201715609813-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 31, 2017 |
| Priority date | Mar 8, 2011 |
| Publication date | Apr 16, 2019 |
| Grant date | Apr 16, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides oxaspiro[2.5]octane derivatives and analogs, methods for preparation thereof, intermediates thereto, pharmaceutical compositions, and uses thereof in the treatment of various disorders and conditions, such as overweight and obesity.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of: and a pharmaceutically acceptable salt or stereoisomer thereof. 2. A compound selected from the group consisting of: and a pharmaceutically acceptable salt or stereoisomer thereof. 3. A pharmaceutically acceptable composition comprising the compound of claim 2 and a pharmaceutically acceptable excipient. 4. A compound represented by: or a pharmaceutically acceptable salt thereof. 5. A pharmaceutically acceptable composition comprising the compound of claim 4 , and a pharmaceutically acceptable excipient. 6. A method of treating and/or controlling obesity, comprising administering to a patient in need thereof an effective amount of the compound of claim 2 . 7. The method of claim 6 , wherein the patient is a human. 8. The method of claim 7 , wherein the patient has a body mass index greater than or equal to about 25 kg/m 2 before the administration. 9. The method of claim 6 , wherein after administration, thioredoxin 1 is not significantly present in the testes of a male patient.
Assignees
Inventors
Classifications
Anorexiants; Antiobesity agents · CPC title
with only one oxygen atom as ring hetero atom in the oxygen-containing ring · CPC title
with hydrocarbon radicals, substituted by nitrogen atoms (nitro, nitroso radicals C07D303/08) · CPC title
Spiro-condensed systems · CPC title
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10259796B2 cover?
- The invention provides oxaspiro[2.5]octane derivatives and analogs, methods for preparation thereof, intermediates thereto, pharmaceutical compositions, and uses thereof in the treatment of various disorders and conditions, such as overweight and obesity.
- Who is the assignee on this patent?
- Zafgen Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D303/46. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).